Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Santen’s Corporate Philosophy Framework
Santen’s Corporate Philosophy Framework
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Digital Transformation
Digital Transformation
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP
Medium-term Management Plan
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Development Process
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2025
IR News
2025 IR News
RSS
IR News
05.21.2025
Santen and Bayer Yakuhin Launch New Pre-Filled Syringe for EYLEA® 8 mg, EYLEA® 8 mg intraocular injection kit 114.3 mg/mL
05.21.2025
Santen Announces FY2025-2029 Medium-Term Management Plan
05.13.2025
Summary of Consolidated Financial Results for the Year Ended March 31, 2025 (IFRS)
05.13.2025
Santen Announces Share Buyback
05.13.2025
Santen Announces Reversal of General Reserve
05.01.2025
Notice of Board of Director and Corporate Auditor Nominations
04.04.2025
Santen Announces China NMPA Approval of Tapcom🄬 in Patients with Open-Angle Glaucoma or Ocular Hypertension
03.31.2025
Santen Receives Positive CHMP Opinion in Europe for Ryjunea🄬 for slowing the progression of paediatric myopia
03.28.2025
Santen Receives Excellence Award at NIKKEI Integrated Report Award 2024
03.18.2025
Santen launches RYJUSEA🄬 Mini ophthalmic solution 0.025% Japan’s first ophthalmic solution for slowing myopia progression
03.13.2025
Santen launches Rocklatan🄬 ophthalmic solution (netarsudil 0.02% and latanoprost 0.005%), in Singapore for the treatment of patients with open-angle glaucoma or ocular hypertension
03.11.2025
Notice of Corporate Officer Changes
02.06.2025
Santen Announces Cancellation of Treasury Shares
02.06.2025
Revision of Dividend Forecast
02.06.2025
Santen Reports the 3rd Quarter Fiscal 2024 Consolidated Performance
